MYTOLAC^® is the first generic containing lanreotide indicated in the treatment of acromegaly, enteropancreatic-NETs and carcinoid syndrome^1*

^PrMYTOLAC^® [lanreotide (as acetate) injection] is indicated for:

• The treatment of enteropancreatic neuroendocrine tumours (NETs) in adult patients with Grade 1 or a subset of Grade 2 (equivalent to Ki67 <10%) unresectable, locally advanced or metastatic disease, to delay progression. The effectiveness of lanreotide is based on a phase III placebo-controlled study which demonstrated a benefit in progression-free survival in patients classified with stable disease by RECIST criteria (<20% growth) over 12 to 24 weeks. There was no evidence of an overall survival benefit. Data on hindgut tumours were limited.
• The treatment of adult patients with carcinoid syndrome; when used, MYTOLAC^® reduces the administration frequency of short-acting somatostatin analog rescue therapy.
• The long-term treatment of adult patients with acromegaly due to pituitary tumours who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
• The relief of symptoms associated with acromegaly. The goal of treatment in acromegaly is to reduce growth hormone (GH) and age adjusted insulin-like growth factor 1 (IGF-1) levels, and where possible, to achieve normalization of their values.